NTRA: Double-digit MRD growth, broad Signatera adoption, and new clinical data drive future expansion
Moins d'1 minute de lecture
Record attendance marked the conference, with strong financial results and double-digit MRD revenue growth. Clinical adoption of Signatera is broadening, supported by robust trial data and expanding reimbursement, while new product opportunities and trials are advancing.
Based on Natera, Inc. [NTRA] Piper Sandler 37th Annual Healthcare Conference Audio Transcript — Dec. 3 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr